Replimune Gets Third Try at FDA Approval After Makary Departure - WSJ

Replimune Gets Third Try at FDA Approval After Makary Departure WSJ Replimune to resubmit twice-rejected drug for approval after FDA shakeup CNBC Replimune Soars After FDA Reconsiders Denial of Skin Cancer Drug Bloomberg.com FDA to prioritize RP1 melanoma review in cancer killing 8,500 a year Stock Titan Replimune gets third chance at US approval for skin cancer drug Reuters